Corrigendum to ``Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study''. [Journal of affective disorders 271 (2020) 1-8]

Objectives Accumulating evidence has implicated that brain derived neurotrophic factor (BDNF) is thought to be involved in the pathophysiology of depression, but its correlation with ketamine’s antidepressant efficacy focusing on Chinese individuals with depression is not known. This study was aim to determine the correlation of plasma BDNF (pBDNF) concentrations and ketamine’s antidepressant efficacy. Methods Ninety-four individuals with depression received six intravenous infusions ketamine (0.5 mg/kg). Remission and response were defined as Montgomery-Asberg Depression Rating Scale (MADRS) scores less than 10 and a reduction of 50% or more in MADRS scores, respectively. Plasma was collected at baseline and at 24 h and 2 weeks after completing six ketamine infusions (baseline, 13 d and 26 d). Results A significant improvement in MADRS scores and pBDNF concentrations was found after completing six ketamine infusions compared to baseline (all ps < 0.05). Higher baseline pBDNF concentrations were found in ketamine responders/remitters (11.0 ± 6.2/10.1 ± 5.8 ng/ml) than nonresponders/nonremitters (8.0 ± 5.5/9.2 ± 6.4 ng/ml) (all ps < 0.05). Baseline pBDNF concentrations were correlated with MADRS scores at 13 d (t = − 2.011, p = 0.047) or 26 d (t = − 2.398, p = 0.019) in depressed patients (all ps < 0.05). Subgroup analyses found similar results in individuals suffering from treatment refractory depression. Conclusion This preliminary study suggests that baseline pBDNF concentrations appeared to be correlated with ketamine’s antidepressant efficacy in Chinese patients with depression.

Download Full-text

Pramipexole in unipolar and bipolar depression

Psychiatric Bulletin ◽

10.1192/pb.28.12.438 ◽

2004 ◽

Vol 28 (12) ◽

pp. 438-440 ◽

Cited By ~ 6

Author(s):

Eromona Whiskey ◽

David Taylor

Keyword(s):

Affective Disorders ◽

Bipolar Depression ◽

Case Reports ◽

Unipolar Depression ◽

Clinical Implications ◽

Clinical Use ◽

Limited Data ◽

Double Blind ◽

Reference Sections ◽

Wide Range

Aims and MethodTo review the evidence for this use of pramipexole in the treatment of unipolar and bipolar depression, a literature search on Embase and Medline was conducted in December 2003. The search was updated in July 2004. The reference sections of retrieved papers were searched for further relevant references.ResultsThere are limited data on the clinical use of pramipexole in affective disorders. Only two double-blind trials in bipolar depression and one in unipolar depression were retrieved. Most information is in the form of case reports and open studies. No dose-response relationships have been established and a wide range of doses has been employed in the reports.Clinical ImplicationsIn view of the fact that the evidence for the use of pramipexole is still limited at the time of writing, its routine clinical use cannot be recommended. The data appear promising, but further research is required to determine its role in affective disorders.

Download Full-text

Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: a preliminary study

PeerJ ◽

10.7717/peerj.10208 ◽

2020 ◽

Vol 8 ◽

pp. e10208

Author(s):

Wei Zheng ◽

Yan-Ling Zhou ◽

Cheng-Yu Wang ◽

Xiao-Feng Lan ◽

Bin Zhang ◽

...

Keyword(s):

Working Memory ◽

Bipolar Depression ◽

Visual Learning ◽

Verbal Learning ◽

Depression Symptoms ◽

Speed Of Processing ◽

Treatment Resistant ◽

Observational Period ◽

Preliminary Study ◽

Over Time

Objective The N-methyl-D-aspartate subtype glutamate receptor antagonist ketamine has rapid antidepressant and antisuicidal effects in treating treatment-resistant bipolar depression (TRBD). The neurocognitive effects of repeated ketamine infusions in TRBD are not known. Methods Six intravenous infusions of ketamine (0.5 mg/kg over 40 min) were administered on a Monday–Wednesday–Friday schedule during a 12-day period on 16 patients with TRBD followed by a 2-week observational period. The assessment of neurocognitive function was conducted using the MATRICS Consensus Cognitive Battery at baseline, 13 and 26 days. Tasks were designed to test speed of processing, working memory, visual learning and verbal learning. Results A significant improvement was found only in scores of speed of processing (F = 9.9, p = 0.001) after a 2-week observational period, which was accounted for by the improvement of depression symptoms. There were no significant changes over time in terms of working memory, visual learning and verbal learning. Pearson correlation analysis showed that the improvement of depression symptoms through six ketamine infusions was greater among TRBD patients with lower working memory at baseline (r = 0.54, p = 0.03). In multiple regression analysis, the significant correlation was still maintained (beta = 0.67, t = 2.2, p = 0.04). Conclusion This preliminary study indicated that six ketamine infusions were not harmful but were slightly beneficial for speed of processing in TRBD. However, this change was mainly accounted for the improvement of depression symptoms over time. Lower baseline working memory appears to be associated with greater antidepressant response after completion of six ketamine infusions in patients with TRBD.

Download Full-text

Everyday creativity and bipolar and unipolar affective disorder: preliminary study of personal and family history

European Psychiatry ◽

10.1017/s092493380000328x ◽

1992 ◽

Vol 7 (2) ◽

pp. 49-52 ◽

Cited By ~ 5

Author(s):

R Richards ◽

DK Kinney ◽

H Daniels ◽

K Linkins

Keyword(s):

Bipolar Disorder ◽

Family History ◽

Affective Disorder ◽

Affective Disorders ◽

Bipolar Disorders ◽

Data Support ◽

History Of ◽

Preliminary Study ◽

Everyday Creativity ◽

Underlying Mechanisms

SummaryPreliminary new data support the enhancement of ‘everyday’ creativity among those persons with bipolar disorders who manifest milder rather than more severe mood elevations, and among certain individuals who are likely to carry bipolar liability but themselves show no clinical mood elevations – in this case, unipolar depressives with a family history of bipolar disorder, when compared with depressives lacking this history. Creativity was assessed using the lifetime creativity scales (Richards el al, 1988). Underlying mechanisms may be multifactorial and complex. Results suggest that both personal and family history should be considered when making predictions concerning creativity and affective disorders.

Download Full-text

P.319 Intravenous ketamine long-term use in two bipolar depression cases: 1-year follow-up

European Neuropsychopharmacology ◽

10.1016/j.euroneuro.2019.09.339 ◽

2019 ◽

Vol 29 ◽

pp. S228

Author(s):

I. Laria Bustillo ◽

N. Olazabal ◽

S. Bustamante ◽

M.A. Madrazo ◽

L. Osa ◽

...

Keyword(s):

Bipolar Depression ◽

Intravenous Ketamine

Download Full-text

Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression

The International Journal of Neuropsychopharmacology ◽

10.1017/s1461145710001203 ◽

2011 ◽

Vol 14 (4) ◽

pp. 545-551 ◽

Cited By ~ 14

Author(s):

Linda Mah ◽

Carlos A. Zarate ◽

Allison C. Nugent ◽

Jaskaran B. Singh ◽

Husseini K. Manji ◽

...

Keyword(s):

Dopamine Receptor ◽

Receptor Agonist ◽

Bipolar Depression ◽

Neural Mechanisms ◽

Dopamine Receptor Agonist ◽

Antidepressant Efficacy

Download Full-text

Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

Biological Psychiatry ◽

10.1016/j.biopsych.2011.12.010 ◽

2012 ◽

Vol 71 (11) ◽

pp. 939-946 ◽

Cited By ~ 425

Author(s):

Carlos A. Zarate ◽

Nancy E. Brutsche ◽

Lobna Ibrahim ◽

Jose Franco-Chaves ◽

Nancy Diazgranados ◽

...

Keyword(s):

Bipolar Depression ◽

Randomized Controlled ◽

Antidepressant Efficacy

Download Full-text

The Brief Assessment of Cognition In Affective Disorders (BAC-A):Performance of patients with bipolar depression and healthy controls

Journal of Affective Disorders ◽

10.1016/j.jad.2014.05.002 ◽

2014 ◽

Vol 166 ◽

pp. 86-92 ◽

Cited By ~ 22

Author(s):

Richard S.E. Keefe ◽

Kolleen H. Fox ◽

Vicki G. Davis ◽

Courtney Kennel ◽

Trina M. Walker ◽

...

Keyword(s):

Affective Disorders ◽

Bipolar Depression ◽

Healthy Controls ◽

Brief Assessment ◽

A Performance

Download Full-text

Maintenance ECT in Affective Disorders

European Psychiatry ◽

10.1016/s0924-9338(09)70601-7 ◽

2009 ◽

Vol 24 (S1) ◽

pp. 1-1

Author(s):

D. Barrocas ◽

R. Coentre ◽

I. Chendo ◽

T. Mendes ◽

M. Abreu ◽

...

Keyword(s):

Affective Disorders ◽

Hospital Admissions ◽

Bipolar Depression ◽

Efficacy And Safety ◽

Therapeutic Tool ◽

Frequent Relapses ◽

Maintenance Ect ◽

Santa Maria ◽

Term Management

ECT is the most powerful therapeutic tool in the treatment of acute mood episodes. However, data on the efficacy and safety of ECT in the long term management of affective disorders is lacking, despite overwhelming rates of chronicity and/or frequent relapses among patients with unipolar and bipolar depression. In this presentation we will review the data of the ECT unit of Hospital de Santa Maria, Lisboa, on maintenace ECT (m-ECT) in these patients. We compare intra and inter-individual evolution prior and after the institution of m-ECT. Considering the number of hospital admissions, mood symptoms and other parameters, our data support the use of this technique as a prophylatic approach for patients with mood disorders and a previous good response to ECT in the acute phase of disease.

Download Full-text